TF and Alzheimer disease: The ratio of brain-type transferrin to serum-type transferrin in the CSF is altered in neurological diseases such as Alzheimer’s disease and Parkinson’s disease, demonstrating the clinical potential of brain-derived glycoproteins in the CSF [8].